The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A.
 
Arjun Vasant Balar
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Dragonfly Therapeutics; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Abbott Molecular; Arquer Diagnostics; ArTara Therapeutics; Asieris Pharmaceuticals; AstraZeneca; BioClin Therapeutics; Bristol-Myers Squibb; Cepheid; CG Oncology; Eisai; EnGeneIC; Ferring; Imagin Medical; Janssen; MDxHealth; Medac; Merck; Pfizer; Photocure; Roviant Sciences; Seagen; Sesen Bio; Theralase; TMC Innovation; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FKD Therapies; Heat Biologics; Merck; Photocure; SWOG
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Girish S. Kulkarni
Honoraria - AbbVie; Sanofi; TerSera
Consulting or Advisory Role - Bayer; Ferring; Janssen; Merck; Roche; Theralase
Research Funding - AstraZeneca; Bristol-Myers Squibb; Merck; Theralase
 
Edward M. Uchio
Research Funding - Ambry Genetics; Bayer; Clovis Oncology; GenomeDx; Genomic Health; Janssen Oncology; Merck; Merit Medical Systems; Myovant Sciences; Myovant Sciences; Myriad Genetics; Pfizer
(OPTIONAL) Uncompensated Relationships - Bayer; Genomic Health; Janssen Oncology; Merck; Myriad Genetics; Pfizer
 
Joost L. Boormans
Consulting or Advisory Role - Ambu; Bristol-Myers Squibb; Janssen; MSD; Roche
Research Funding - Decipher Biosciences
 
Mathieu Roumiguié
Honoraria - Astellas Pharma; AstraZeneca; Ferring; Ipsen; Pierre Fabre
Consulting or Advisory Role - Arquer Diagnostics; Invectys; Janssen
 
Laurence Eliot Miles Krieger
Honoraria - Astellas Pharma; Ferring; Ipsen; Janssen-Cilag; Janssen-Cilag; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi
Speakers' Bureau - Abbvie; Janssen; Janssen-Cilag; Merck Sharp & Dohme; Roche
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Janssen-Cilag (Inst); Roche (Inst)
Expert Testimony - Astellas Pharma; Ipsen; Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Ipsen; Janssen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer
 
Eric A. Singer
Research Funding - Astellas Medivation
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Dragonfly Therapeutics; Fidia Farmaceutici S. p. A.; Merck; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Ho Kyung Seo
Honoraria - Astellas Pharma; Boryung; Hanmi
Consulting or Advisory Role - MSD Oncology
Speakers' Bureau - Bristol-Myers Squibb-Ono Pharmaceutical; MSD Oncology; Roche
Research Funding - AstraZeneca; AstraZeneca; Janssen Oncology; MSD Oncology; Ono Pharmaceutical; Roche
 
Hiroyuki Nishiyama
Consulting or Advisory Role - MSD
 
Badrinath R. Konety
No Relationships to Disclose
 
Kijoeng Nam
Employment - Merck
 
João Paulo Zambon
No Relationships to Disclose
 
Ekta Kapadia
Employment - Merck
 
Ronald De Wit
Honoraria - Merck Sharp & Dohme; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer